Natalie Schub
Kiel, SH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
Journal: Nature medicine
Published: July 06, 2026
Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy.
Journal: Cardio-oncology (London, England)
Published: May 07, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.
Journal: Journal of hematology & oncology
Published: April 06, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.
Journal: Blood cancer discovery
Published: December 03, 2025
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report.
Journal: Frontiers in immunology
Published: November 19, 2025
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.
Journal: Blood cancer journal
Published: November 08, 2025
Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.
Journal: Transplantation
Published: February 28, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.
Journal: HemaSphere
Published: January 30, 2025
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.
Journal: International journal of molecular sciences
Published: October 31, 2024
Last Updated: 09/26/2026